{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-022527","form_type":"8-K/A","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2022-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.096174+00:00","generated_at":"2026-06-25T04:29:53.435731+00:00","sec_items":["1.01","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TherapeuticsMD adopts bylaw amendment facilitating acquisition by Athene Parent via tender offer and merger","bullets":["Bylaw amendment adopted May 27, 2022, makes Nevada control share statutes inapplicable to the merger agreement with Athene Parent and Merger Sub.","Amendment enables cash tender offer for all outstanding TXMD common stock and subsequent merger.","This 8-K/A corrects item number from 1.01 to 5.03; no disclosure changes from the original June 3, 2022 filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-022527","json":"https://secwatch.observer/filing/0001564590-22-022527.json","markdown":"https://secwatch.observer/filing/0001564590-22-022527.md","text":"https://secwatch.observer/filing/0001564590-22-022527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000156459022022527/0001564590-22-022527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000156459022022527/txmd-8ka_20220527.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T04:29:53.435731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}